And support their vision by investing at the intersection of...
Fatima Cody Stanford , MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS
Innovation Council
Bio 
Confidential
Julien L. Pham , MD, MPH
Founder & Managing Partner
Julien L. Pham, MD, MPH has over fifteen (15) years of leadership experience in clinical settings and in emerging medical technology companies. During this time, he has held various research and teaching positions, and has received multiple awards including excellence in teaching awards from AOA and Harvard Medical School. He is a board-certified Internal Medicine doctor, and a Nephrologist who has received NIH research funding for translational research while at Harvard, and has published in basic and translational science, and health policy fields.
Most recently, Dr. Pham was recruited to scale up and spin out a clinical-stage gene therapy biotechnology company in the Oncology and Diabetes space from MD Anderson Cancer Center. He led strategy and fundraising through an IPO (NASDAQ: GNPX) in 2018, then served as President and COO until Q4 2020, with P&L and management responsibilities for manufacturing, clinical strategy and operations, regulatory, and business development. Most recently, Genprex obtained FDA’s Fast Track Designation in late 2019 and raised $22.5 million via a shelf registered Form S-3 offering in Q1 2020.
Prior to that, in 2013, Dr. Pham co-founded and served as Chief Medical Officer of RubiconMD, a digital health company that connects primary care providers to specialists for additional guidance and opinions on medical cases (eConsults). RubiconMD has recently raised a Series C with the likes of Deerfield Management and Optum Ventures.
Prior to RubiconMD, he served on the faculty at Harvard Medical School and was clinical Nephrology staff at Mass General Brigham, where in 2012, he launched RHINNO, one of the first skunkworks innovation lab inside a hospital and was on the founding committee of Harvard Medical School’s Brigham & Women’s Hospital Innovation Hub (iHub).
As an investor, Dr. Pham is often sought out for his unique expertise in evaluating both biotech and digital health companies. Since 2015, he has been exposed to emerging global companies in pre-seed stage, some of which have now become rapid growth stage companies, including a 2020 CB Insights “50 future unicorns” list. Personally, he has invested in 7 early-stage companies, including RubiconMD, Circulation (acquired 2018), AceUp, Hilltop Bio, Nurse-1-1, Health Vector, and Quantivly.
Dr. Pham volunteers his time as a clinician/advisor for ASSORV, a French non-profit organization founded in 1992 by his family and which operates 3 orphanages in Vietnam. He is also an experienced non-profit board member and has been the most recent Chair of the Board of Essential Partners, a Cambridge-based non-profit organization which for the past 30 years, has fostered dialogue where conflicts are driven by differences in identity, beliefs, and values.
Dr. Pham received his MD from the University of Washington School of Medicine. He was a combined Medicine/Pediatrics resident and chief resident at the University of Illinois at Chicago, and completed his fellowship in Nephrology at the Harvard joint program. He obtained his MPH in Clinical Effectiveness at the Harvard Chan School of Public Health.
Education :
Reference links :
Christine Hsieh , PhD
Operating Partner
Deep Technology, Data & Strategic Vision, Neuro-cognitive Science
As an MIT-trained scientist turned founder/CEO and startup executive, Christine has a unique blend of expertise in deep technology, data, and strategic vision when it comes to building new ventures.
Her early interest in developing new health technologies led her to work at the intersection of psychology, new ventures, and science commercialization. Over the years Christine has won many awards recognizing her work and commitment to cutting edge R&D and health innovation.
Most recently she was the Chief Strategy and Research Officer at DayToDay Health, a digital care management company. She was recruited to develop and execute a cross-functional strategy to capture new markets and enabled launch of the first digital product within four months of starting development. Under her leadership the company was able to bridge siloes across commercial, product, clinical, and R&D teams, enabling scaling of operations for three countries within three year’s time. After serving 7000+ acute care patients around the world even through the Covid pandemic, DayToDay was acquired by Babylon Health, a publicly traded virtual care company.
Prior to DayToDay Health Christine launched her entrepreneurial career as Founder and CEO of Salubris Analytics. In this role she built a grant-launched, highly capital efficient venture focused on behavior change for chronic care management. She led the development of a digital product with personalization features and algorithms, science-based content, and analytics. Christine then partnered with leading US healthcare systems to validate the solution and closed a revenue-generating contract with a prominent three million member insurer.
In her doctoral work at the Harvard-MIT Division of Health Sciences and Technology, Christine won independent research funding to design novel personalized treatments for depression, anxiety, and pain. The new treatment significantly reduced depressive symptoms and was published in national conferences and journals. Prior to her thesis work she also developed bioimaging and neuroimaging technologies in prominent labs at Massachusetts General Hospital and Massachusetts Eye and Ear Infirmary, and tangible interfaces at the MIT Media Lab.
Christine is currently most passionate about redefining impact on health by shifting the ways we work, live, and play to be more health-enhancing. She is an Entrepreneur in Residence at MIT and also serves on the Board of Directors of HealthTech Build, a Boston-based nonprofit creating catalytic community events accelerating healthcare and life sciences technology adoption.
Christine completed her Bachelor of Science at Rutgers University, graduating in the top five students majoring in Physics in her class as well as majoring in Cell Biology and Neuroscience.
In her spare time, she writes about happy high performance, and loves hiking and skiing around the world with her husband and daughter.
Education :
Reference links :
Stanley O. King II, PhD
Entrepreneur-in-Residence
Intellectual Property and Licensing, Strategy, Partnership & Business Development
Stanley O. King II, PhD is a neuroscientist, social entrepreneur, and corporate development executive. He has over ten (10) years of life science business and corporate development experience. His interest in commercializing early-stage technologies and venture creation has led him to roles at the interface of business strategy, product management, licensing, entrepreneurship, and biomedical research. He’s been responsible for sourcing and evaluating innovations that span medical devices, synthetic biology, therapeutics, diagnostics, genetics, and digital health. He has led and executed well over a hundred deals, worth millions of dollars, with research disease foundations, pharma, biotech, and healthcare companies globally.
Most recently, as the Executive Vice President of Corporate Development at Emulate Inc., a Harvard spinout, Stan developed the go-to market strategy and helped secure over $100M in equity financing alongside the founding CEO. Operationally he was responsible for strategic partnerships and research collaborations, designed and lead the global beta testing program for the first product launch, established academic research centers of excellence in the UK and Europe, and lead due diligence for all licensing and acquisitions. Prior to joining Emulate, Stan worked in business development and licensing roles at Boston Children’s Hospital’s Technology Innovation and Development Office, the Wyss Institute for Biologically Inspired Engineering at Harvard, the MIT Technology Licensing Office, and University of Virginia Licensing and Ventures. In these roles, he evaluated the commercial potential of countless early-stage life science and healthcare technologies, managed patent portfolios of more than 1,000 life science and medical device inventions, and advised innovative academic and physician founders.
Stan founded a social enterprise, Door to the Outdoors, focused on diversifying outdoor recreation and worked in Kigali, Rwanda at Akazi Kanoze: Youth Livelihoods Project, an organization focused on increasing youth employment and fostering an entrepreneurship ecosystem for economic development. Stan remains engaged in the community as a current member of the UNCF New England Leadership Council and past board member for the non-profit Families for Depression Awareness. He also volunteers his time mentoring startup founders and advises STEM students curious about alternative careers. A neuroscientist by training, he has received research fellowships from Marine Biological Laboratory, Cold Spring Harbor Laboratory, Max Planck Institute for Human Development, and American Psychological Association.
Education :
Reference links :
Lloyd Appel , CPA, CFA
CFO
Lloyd has over 25 years of experience with alternative asset firms, including hedge funds and life sciences / technology venture capital. As a data‐focused finance leader, he drives efficiency improvements through financial, operations, and technology insights.
As an experienced Chief Financial Officer with a background in public and private accounting, SEC reporting, and U.S. and EU regulatory compliance, Lloyd also has a strong history of assembling, turning around, and leading rapid-response, high-performing finance teams, which in turn gives investors the comfort of knowing that goals are being achieved and their investments are safe.
For the last 11 years, Lloyd was the CFO of two venture capital firms where he was also responsible for all non-investment matters, including compliance, operations, legal, human resources and benefits, insurance, facilities and technology.
As the first CFO at Aisling Capital, a top global Life Sciences firm, he helped turn around the finance department and oversaw accounting, compliance, and operations for 4 funds and $1.6 billion AUM. At New Science Ventures in the Life Science and Technology space, with 20 funds and $600 million in total commitments, he improved fund operations, IT, compliance, and financial reporting. Previously, Lloyd was the CFO or controller of a number of hedge funds (Millenium Partners, MJM Partners, Artemis Advisors, Lagrange Capital), as well as the controller of ING Furman Selz, a large alternative asset multi-strategy platform. At these hedge funds, Lloyd specialized in introducing new systems and improving both investor and portfolio reporting. Lloyd has also worked as a securities analyst and attended many IPO roadshows and industry conferences that featured the companies of the first internet boom.
At Third Culture Capital, Lloyd is helping the venture funds launch by providing strategic guidance, setting up and maintaining books and records, writing policies, assisting with service provider selections and coordinating compliance responsibilities.
Lloyd began his career at BDO, where he left as a financial services audit manager after over seven years. He graduated from Queens College with a BA in Accounting and Economics.
Education :
Reference links :
Denise Marks , CPA, MBA
Advisor
VC Operations, Finance, Compliance
Denise has over 25 years’ experience in the VC/PE industry, and is currently the CFO of CareQuest Institute for Oral Health, a large foundation which is a purpose-driven enterprise and a leader in oral health with a mission to improve the oral health of all. From 2003 to 2019, she held multiple roles including Chief Administrative Partner, Chief Compliance Officer and Chief Financial Officer at SV Health Investors (SVHI), an international multi-sector, multi-stage healthcare focused venture capital and growth equity firm with over $3B in historical commitments.
Prior to joining SVHI, Denise was the VP Finance & Administration and a Managing Director at CMGI @Ventures, the venture capital affiliate of CMGI, where she was responsible for all financial and operational aspects of the firm’s venture arm. Prior to joining CMGI @Ventures, Denise was a manager in the Technology Group of PwC LLP. She spent her last two years in the firm’s Entrepreneurial Services Center in Cambridge, MA, working with early stage and rapidly growing technology-based companies advising them on such areas as structuring M&A transactions, revenue recognition and equity related issues. Prior to PwC, Denise worked in commercial banking at Fleet Bank, NA (now Bank of America).
Denise serves on a variety of boards of directors and is active in philanthropy. She currently serves on the boards of the National Venture Capital Association, Shore Country Day School, Dress for Success Boston and Women in Alternative Assets. She earned her Bachelor of Science in Finance from Penn State University and a joint MS/MBA in Accounting from Northeastern University Graduate School of Professional Accounting
Education :
Reference links :
Ravi Thadhani , MD, MPH
Advisor
Medicine, Academic Leadership, Translational and Clinical Research
As the Chief Academic Officer of Mass General Brigham (MGB, formerly Partners Healthcare), Dr. Thadhani oversees a $1.8 billion research enterprise. He has 25 years of experience in Executive Academic Medical Administration, Clinical and Translational Investigation, and Medical Education including his current role as CAO and Dean for Faculty Affairs for MGB and Professor of Medicine at Harvard Medical School (HMS), and previously as Vice Dean of Research and Chair of the Department of Biomedical Sciences, both at Cedars Sinai Medical Center in Los Angeles, and Chief of the Division of Nephrology at the Massachusetts General Hospital (MGH), Boston, Massachusetts.
He currently serves as HMS Faculty Dean for Academic Programs, chairing the MGB Committee on Senior Appointments and serving on the Council of Academic Deans. As a member of MGB’s executive leadership team, Dr. Thadhani works together with senior leadership across the system on a number of system strategic initiatives. He is a standing consultant to the FDA’s Cardio-Renal Division (2020-2024). He has extensive experience in developing regulatory and marketing strategies with small Biotech, diagnostic and device makers, as well as large Pharma. He has co-founded startup biotech companies and licensed patents to Industry. He holds several patents, including for a novel diagnostic for pre-eclampsia (marketed in the EU).
Dr. Thadhani received his MD from the University of Pennsylvania and his MPH from the Harvard Chan School of Public Health. He trained at Massachusetts General Hospital and Harvard Medical School and was Chief of Nephrology from 2013-2017
Education :
Reference links :
Guy Fish , MD, MBA
Special Advisor
Medicine, Strategy & Entrepreneurship, Venture Capital, Governance
Dr. Fish has over 30 years of experience in healthcare, life sciences, and technology. He has particular interest in bioprocessing & biomanufacturing, digital health, personalized medicine, and cost reducing strategies ranging from value-based reimbursement to biosimilars.
Dr. Fish was recently acting CEO of Next Phase Therapeutics, an international drug discovery company developing a novel exosome-based platform for treating dermatological pathologies with topical delivery. Prior to that, he was CEO and board member of Cellanyx, a company developing a first-in-class live tumor cell diagnostic platform.
Prior to that, he was a consultant and VC at Fletcher Spaght for 18 years, and retired as Sr. Vice President and Strategic Advisor. There, he helped launch the corporate ventures arm, raising and winding down 2 funds, of $30M and $100M respectively. Dr. Fish has also worked as a securities analyst in the medical devices sector for Sanford Bernstein, as a healthcare consultant at The Boston Consulting Group, and as a solo practice physician.
Dr. Fish is a Trustee Advisor of Beth Israel Deaconess Medical Center in Boston, where he previously chaired the Patient Care Committee, and holds membership on the Patient Care Assessment and Quality Committee, and Medical Education Committee. He has served as Chairman of the Licensing Board for Dubai Health Care, as well as the Licensing Committee for the Board of Registration in Medicine for the Commonwealth of Massachusetts. Dr. Fish is currently a member of the Board of Directors of Altarum Institute, Phase Biosciences, and is a Board observer of Proteus Digital Health.
Dr. Fish holds an MBA from the Yale School of Management, an MD from the Yale School of Medicine, and an AB in biochemistry from Harvard College. He is Board Certified in Internal Medicine.
Education :
Reference links :
Maria V Lopez-Bresnahan , MD, MBA, FAAN
Advisor
Dr. Maria Lopez-Bresnahan is a senior biopharmaceutical executive with more than 25 years of industry experience developing new treatments for neurologic diseases, including rare genetic neuromuscular and neurodegenerative disorders, from early phases through post-approval lifecycle management. Most recently she served as SVP for Translational Medicine and Clinical Development at Voyager Therapeutics. Previously she was VP of Clinical Research, Neuroscience at Alkermes, Inc. and VP of Neurology Clinical Development at Vertex Pharmaceuticals where she led clinical teams developing drugs across CNS indications from Phase 1 through registration. At Pfizer Inc. she was Head of Neuromuscular Clinical Research in the Rare Disease Research Unit, and Therapeutic Area Head for Neuroscience in the Medicines Development Group leading a team responsible for strategy and planning of drug development in neurology and psychiatry. Dr. Lopez-Bresnahan held leadership positions at Merck Serono, where she was responsible for development of CNS drugs for immunologic and neurodegenerative disorders through registration and commercialization. She also served as SVP and Global Head for Medical and Scientific Affairs at inVentiv Health Clinical, where she led subspecialty medical teams executing drug development programs for pharmaceutical clients.
Dr. Lopez-Bresnahan serves on the Scientific Advisory Board of SYTE.bio a biotechnology company developing DNA and RNA therapeutics. She is a Founding Venture Partner with AccelHUB Venture Partners, providing biotechnology expertise to partner accelerator programs for international startups.
Dr. Lopez-Bresnahan received a BA from Yale University, an MD from New York University School of Medicine, and an MBA from Northeastern University. A Fellow of the American Academy of Neurology, she completed her neurology residency and a fellowship in neuroimmunology at the Massachusetts General Hospital and the Harvard Medical School, where she served as Assistant Clinical Professor of Neurology.
Education :
Reference links :
Doug Treco , PhD
Special Advisor
Biopharma, Bio-entrepreneurship, Executive Leadership, Board governance
Dr. Treco has over 30 years of experience as a biopharma executive. He co-founded Ra Pharmaceuticals, Inc. in 2008 and served as Chief Executive Officer and a member of the Board of Directors from its inception until July 2020 following the acquisition of Ra Pharma by UCB S.A. Previously, he was an Entrepreneur-in-Residence at Morgenthaler Ventures from January 2008 to May 2014. In 1988, he co-founded Transkaryotic Therapies Inc. (TKT), a multi-platform biopharmaceutical company developing protein and gene therapy products which was acquired by Shire Pharmaceuticals Group plc in 2005.
Dr. Treco was a Visiting Scientist in the Department of Molecular Biology at Massachusetts General Hospital and a Lecturer in Genetics at Harvard Medical School from 2004 to 2007. He received his Ph.D. in Biochemistry and Molecular Biology from the State University of New York at Stony Brook and performed postdoctoral studies at the Salk Institute for Biological Studies and Massachusetts General Hospital. Dr. Treco currently serves on the boards of directors of CRISPR Therapeutics and Inozyme Pharma.
Education :
Reference links :
Sylvia Brown , CAP
Special Advisor
Philanthropy, Governance, International Development
A Franco-American dual national, living between London and Providence, RI, Sylvia worked first in international development, from Wall Street to the United Nations High Commissioner for Refugees. Since 2006, and following in the Brown family’s 300-year charitable tradition, she reoriented her professional focus to strategic philanthropy.
Today, as a Chartered Advisor in Philanthropy and a BoardSource Governance Trainer, Sylvia develops education tools under the “Smart Donors… Make a Difference” brand for both individual donors and their financial, legal and tax advisors. As a trustee of the Social Enterprise Greenhouse in Providence, Sylvia is also active in the impact investment space. She has been a past trustee of multiple organizations including the Cairn Trust, and the Localgiving Foundation, in London, UK, the Rhode Island Historical Society, and the John Carter Brown Library.
Sylvia received a B.S. in Economics from the Wharton School at the University of Pennsylvania, and a Master of Arts in International Relations from the University of Pennsylvania.
Education :
Reference links :
Barry Gonder , MBA
Special Advisor
Institutional Fundraising, Portfolio Structure & Strategy, LPAC
Barry has over 35 years of experience building/managing investment companies and programs. He has been directly involved in nearly $30 billion in investments and has been a member of over 35 LPACs.
From 1996-2001, he was the Head of Alternative Investments and Senior Investment Officer at CalPERS where he was hired to create that program. There, he was first to purchase GP interests in both established and new managers; financing the first secondary purchase of a private equity portfolio; and leading over $19 billion of investments into funds, direct and co-investments. Prior to that, at Travelers Insurance, he completed 47 direct investments ($700 million) in private equity and mezzanine debt deals in the US and Europe, in addition to $230 million into buyout and venture capital funds. He also created and managed a corporate VC program ($50 million).
Most recently, he was a Managing Partner of GroveStreet (previously GroveStreet Advisors) where he managed a team of about 40 investment professionals. Over the course of 18 years, he invested a total of $9 billion on behalf of clients of the firm, which included pension funds, sovereign wealth funds, family offices and financial institutions in the U.S., Middle East, Israel, Europe, Australia and Asia.
Barry started his career at the Federal Reserve Bank, as an analyst on Paul Volker’s research staff where he prepared economic analyses and econometric models, evaluated financial market conditions and the health of the banking system and participated in analyzing Chrysler Corporation in support of the Fed’s bond guarantee.
Barry has a Bachelors’ degree in Economics, Science Technology & Society from Vassar College, an M.S. in Mathematics and Computer Science from NYU, and an MBA from UNC Chapel Hill.
Education :
Reference links :
Christine J. Spadafor , JD, ScM, RN
Venture Partner
Board Governance, Management Consulting, CEO, Attorney, Public Speaker
Christine J. Spadafor is an experienced public and private company board director with deep expertise in risk management, regulatory compliance and quality, and ESG. She has a demonstrated track record leading successful large-scale transformational initiatives at the intersection of strategy, operations, finance and change management initiatives in a broad spectrum of domestic and international health-related companies – including a major academic medical center, hospitals, physician practice groups, biotechnology, medical equipment manufacturing, mental health and clinical social services sectors. She has worked extensively as an advisor to Fortune 500 C-suite executives.
Christine is CEO of SpadaforClay Group, a management consulting firm. She serves as an Independent Director on the boards of highly regulated companies: Kindred at Home, a private company that is the largest provider of home care and hospice services in the US, where she is the Chair of the Quality and Compliance Committee; and Boyd Gaming Corporation, a $3B NYSE-listed company, where she is the Chair of its Governance and Nominating Committee and a member of the Audit Committee. Christine also serves on the Advisory Board of WBUR, one of the premier National Public Radio stations in the US, and is a commentator on the BBC World Service “Business Matters” global radio broadcast and podcast.
Christine graduated from Harvard Law School, and received a Master of Science degree in Physiology from Harvard School of Public Health, which included course work at the Massachusetts Institute of Technology. At MIT, she co-authored “Monitoring the Worker for Exposure and Disease: Scientific, Legal and Ethical Considerations in the Use of Biomarkers” published by Johns Hopkins University, with a professor in the
Science and Technology core. In addition, Christine was a partner in three premier global management consulting firms (The Boston Consulting Group, CSC Index, AlixPartners), was an editor of The Harvard Environmental Law Review, and was selected by the Business Section of the American Bar Association/Direct Women as one of the top 20 female attorneys in the country with expertise for corporate board service.
In addition to her educational background in science and public health, Christine worked as an ICU nurse at the University of Pittsburgh Medical Center, health and environmental scientist at the US Department of Labor and the Environmental Protection Agency, General Counsel at a pediatric hospital, and served as an advisor to the United Nations in China on public health and sustainable environmental issues in third world countries.
For nearly 10 years, Christine dedicated her extensive experience in financial, operational and organizational management to St. Jude’s Ranch for Children – a nonprofit that serves abused, abandoned and homeless children. As CEO, she inherited a nearly bankrupt organization – and against all odds, set the ambitious growth strategy, restructured the corporation and corporate governance, and led the execution of a plan that resulted in an innovative turnaround that received national acclaim. Christine continues to be involved with a number of non-
profit organizations as advisor or board trustee.
Christine is a lecturer on Strategic Leadership in the Visiting Executive Program at Tuck School of Business at Dartmouth, a lecturer at Harvard Kennedy School and is a frequent speaker at seminars and meetings addressing “Women in Leadership” topics: she was a keynote speaker at international conferences sponsored by Harvard Medical School and at the annual meeting of the American Medical Group Association. Christine was a featured speaker at conferences sponsored by the Geisel School of Medicine at Dartmouth and Harvard School of Public
Health. Christine also holds two Doctor of Humane Letters degrees – awarded in recognition of her professional accomplishments and lifelong contributions to vulnerable and at-risk populations.
Education :
Reference links :
Marla Persky , JD
Venture Partner
Global Legal Services, Public & Private Companies, Business Advisor & Strategist
Marla Persky is CEO and President of WOMN LLC, a company dedicated to helping women succeed in the business of law by increasing their knowledge of and acuity with financial drivers, client development, and leadership. Marla retired in 2013 as Senior Vice President, General Counsel and Corporate Secretary for Boehringer Ingelheim USA, where she oversaw a department of over 70 individuals. She was also a member of Boehringer’s executive management team and a director of the company and several of its subsidiaries.
Prior to joining Boehringer Ingelheim, Marla spent 19 years at Baxter International Inc. where she held numerous business and legal positions, the most recent of which was Acting General Counsel and Corporate Secretary. During her career at Baxter, Marla managed global legal services, was General Manager of a $300mm international medical device business, led international crisis management teams, acquired and integrated international businesses, and designed/implemented legal strategies to manage global mass torts. Marla practiced with the Chicago firm of Lurie, Sklar & Simon. Before entering the practice of law, Marla worked in sales and marketing for the Colgate-Palmolive Company.
Marla is currently on the Audit and chairs the Nominating/Governance Committees of Xeris Pharmaceuticals, Inc. (NASDAQ: XERS), a specialty pharmaceutical company that leverages proprietary non-aqueous formulation technology platforms; the Audit and Strategic Planning Committees of the Board of Directors of YGEIA, a medical technology company; and is on the Board of Advisors of Text IQ, a technology company that harnesses the power of artificial intelligence to prevent legal, compliance and reputational disasters. Previously, she served on the Board of Directors of Cytyc Corporation (NASDAQ: CYTYC) a device and diagnostics company. She was also on the Board of Boehringer Ingelheim Corporation, the world’s largest privately owned pharmaceutical company. Marla was a director of Watermark, Inc. a private publisher and broker of children’s literature.
Throughout her career, Marla has focused on improving diversity and inclusion in the legal profession. She has been awarded for her contributions by elite organizations such as the Lawyer’s Collaborative for Diversity and the Connecticut Appleseed Foundation.
Marla was recognized as one of the ten most innovative in-house counsel for her strategy and efforts to increase the opportunities and visibility of women in high profile litigation.
In addition to her corporate activities, Marla is on the Board of several not-for-profit organizations such as the Leukemia & Lymphoma Society, Primary Stages (Off-Broadway Theater Company) and World Neighbors Inc. Marla is a frequent speaker on a variety of subjects including: leadership principles, career development, mentoring, diversity, equity and inclusion, crisis management, and negotiation techniques.
“Work hard, be kind, and amazing things will happen.” -Conan O’Brien
Education :
Reference links :
Steven Haley ,
Venture Partner
Software, Philanthropy, Financial & Technical Advising
Steven is a tech industry veteran, an active seed investor and highly engaged at the leading edge of innovations through his business affiliations and in multiple capacities which include board member, chairman and advisor.
Prior to establishing his private investment group, he was founding Executive Vice President at Juniper Networks, former Vice President at Cisco Systems and former Managing Director and General Manager at StrataCom. He began his technology career as an applications programmer and remains most intrigued by initiatives related to the commercialization of software platforms with particular interest in the scaling of operations to optimize revenue growth.
Steven has also been an active philanthropist for over twenty years having established numerous funds to provide direct financial support for a broad array of initiatives in healthcare, particularly neurosciences and translational medical research. He has also provided grants and established scholarships for K-12 STEM education, a masters and doctoral nursing program, and regularly supports the creative and entertainment arts. He has advised and served on numerous boards and committees including hospitals, museums, and private foundations. Steven co-founded the Brain Science Foundation in 2002 which embraces an entrepreneurial spirit of seed funding promising neuroscience innovations and community of innovators and collaborators.
Education :
Reference links :
Personal note:\r\nI often ask first and second time entrepreneurs if you “presume the posture of success” what does it look like, what do you need to make it happen, what are the constraints & opportunities, what do you perceive to be in your control and what variables are not? Most report, at the top of the list, they need timely access to first-rate talent. Naturally, keeping the talent bar high is essential for a positive outcome, but it is difficult to balance what talent is needed and when to recruit, with that of who is available and where. I tell them to have a contingency plan to raise considerably more capital to accommodate a longer development runway than anticipated; delays in aligning talent; slower commercial adoption; and other unforeseen and disruptive events. I advise to get really good at making tactical decisions because management decision-making agility is a key competitive advantage, particularly if your competition are larger, established entities. Without doubt, time will be of the essence and the bulk of decisions will have to made with less than complete or fully validated information. While it is good to assess at the macro level, leaders and their teams should try to breakdown the process to more manageable elements. While big and bold decisions will have to be made, an operating culture of frequent but smaller incremental decisions move things along while mitigating future damage. Personal and organizational adaptability is key, as is embracing a culture of “over” and “next”. Whatever the issue, a dynamic and innovative early stage company has to get past these hurdles and move forward.
Gary Griffiths , MSBA
Venture Partner
Technology, Entrepreneur, Advisory Boards, Venture Capital
A 35-year veteran of the high-tech industry, Gary has led some of the web’s most innovative companies. Prior to co-founding Wisdom LLP, Gary was CEO of iPass (NASDAQ: IPAS), a leader in global Wi-Fi technology and services, which was acquired by Pareteum, Inc (NASDAQ: TEUM) in February 2019.
A long time Silicon Valley entrepreneur founding a number of start-ups, Gary was also president of products and operations at WebEx, acquired for $3B by Cisco Systems, Inc. Gary was also co-founder and CEO of Everdream Corporation, a SaaS company, from 1999 to 2005, acquired by Dell, and co-founder/CEO at HEAT.net from 1996 until its acquisition by Sega, Inc. in 1999.
Gary has extensive experience overseeing financial and accounting matters as well as strategic initiatives at small technology companies. Gary has served on the board of directors for a number of private and public companies, including Silicon Graphics International Corp. (NASDAQ: SGI), and Janrain, Inc., a customer identity management SaaS company, and others. He is currently an advisor to two private equity funds: Parthenon Capital and Day View Capital.
Gary also volunteers his time as an Associate at Creative Destruction Lab (CDL) a nonprofit organization that delivers an objectives-based program for massively scalable, seed-stage, science- and technology-based companies.
\"Damn the torpedoes, full speed ahead.\"\r\n(That was Admiral David Farragut in the Battle of Mobile Day, 1864).
Education :
Reference links :
Julie Silver , MD
Venture Partner
Associate Professor & Associate Chair, Workforce Diversity, Author, Innovator
Julie K. Silver, MD is an Associate Professor and Associate Chair in the Department of Physical Medicine and Rehabilitation at Harvard Medical School. Dr. Silver has held numerous leadership positions and is a former start-up company founder. She was named the Top Innovator in Medicine in 2012 by The Boston Globe, and the same year her start-up company was listed by Bloomberg/Businessweek as one of the most promising social enterprise companies.
Dr. Silver has a unique approach to innovation with a deep knowledge of dissemination and implementation of science as a driver for the adoption of healthcare products and services. She has spearheaded efforts aimed at elevating the national and international reputation of Spaulding Rehabilitation Hospital (now ranked #2 by US News and World Report) by focusing on key market differentiators in what she calls the “Super 7”: clinical care, research, medical education, technology, innovation, quality, and value. She directs the Harvard Medical School CME accredited course titled Career Advancement and Leadership Skills for Women in Healthcare—that has trained thousands of physicians and other healthcare leaders throughout the United States and internationally. Dr. Silver has received many awards for her work in healthcare and innovation. For example, she received the Outstanding Mentor Award from Mass General Brigham (Partners) for her work mentoring colleagues and trainees at Harvard Medical School in innovation, research, publishing, and leadership. She received the Distinguished Public Service Award from the American Academy of Physical Medicine and Rehabilitation for her cross-cutting work on workforce and patient care disparities with an emphasis on diversity, equity, and inclusion.
Dr. Silver’s research and clinical work has focused on improving gaps in the delivery of healthcare services. Dr. Silver also developed a best practices model for cancer rehabilitation care that hundreds of U.S. hospitals adopted. Recently, Dr. Silver was the technical lead for a workgroup convened by the World Health Organization that focused on clinical practices guidelines for cancer rehabilitation. She has published many scientific reports and is well-known for her ground-breaking work on “impairment-driven cancer rehabilitation” which was initially published in the journal CA: A Cancer Journal for Clinicians--a high impact factor oncology journal that is published by the American Cancer Society. Impairment-driven cancer rehabilitation was subsequently incorporated into the American Cancer Society’s Facts & Figures. Dr. Silver co-founded the Cancer Rehabilitation Group for the American Congress of Rehabilitation Medicine—a research focused interdisciplinary professional society. She has been a subject matter expert in cancer rehabilitation and prehabilitation for the National Institutes of Health, National Cancer Institute, American Academy of Physical Medicine and Rehabilitation, American College of Sports Medicine, and World Health Organization.
Dr. Silver has published many studies and reports in high-impact journals such as The New England Journal of Medicine, The Lancet, The BMJ, and multiple JAMA Network journals. Her work cuts across all specialties, and she has published reports in many specialty journals including PM&R, American Journal of Physical Medicine and Rehabilitation, JAMA Internal Medicine, JAMA Dermatology, Pediatrics, Neurology, Anesthesia and Analgesia, Journal of Cardiothoracic and Vascular Anesthesia, and The Journal of Infectious Diseases. As a nationally recognized expert, Dr. Silver has been invited to give keynotes and workshops at the American Psychiatric Association, American Association for Clinical Endocrinologists, American Academy of Neurology, Infectious Disease Society of America, American College of Cardiology, Pediatric Hospital Medicine, and numerous other medical societies. Dr. Silver has also been an integral part of the development of the Spaulding Research Institute.
Dr. Silver has also authored/edited many books, including the Essentials of Physical Medicine and Rehabilitation which is now in its 4th edition and Easy EMG which is going into its 3rd edition. She has led numerous high impact national strategic initiatives such as the Her Time Is Now Campaign, Be Ethical Campaign, Need Her Science Campaign, and the Walls Do Talk Challenge.
Her work has been featured in hundreds of media outlets including The New York Times, The Wall Street Journal, The Washington Post, The Boston Globe, The London Times and NPR. She has also appeared on numerous TV shows including the CBS Early Show, The Today Show, Fox News, and ABC News.
Dr. Silver is a graduate of the University of California, Davis (B.S., Food Biochemistry); and the Georgetown University School of Medicine (M.D., Physical Medicine and Rehabilitation).
Education :
Reference links :
Robert S. Brown , CPA, MBA
Venture Partner
Healthcare Executive, Corporate Analysis & Control, International Finance, Auditing & Financial Reporting
Robert is the past President and CEO of Ximedica LLC, a full-service ISO-certified and FDA-registered medical device, diagnostics, and digital health technology development company, in which Boston-based private equity firm, SV Health Investors, owns a majority stake.
Prior to Ximedica, Robert served as President NxStage Kidney Care and CFO at NxStage Medical (NASDAQ: NXTM), acquired for $2B by Fresenius Medical Care. He was appointed by the CEO in 2014 to lead NxStage Medical's entry into the dialysis service business and grow NxStage Kidney Care into a leading provider focused on home care. Robert served as NxStage CFO for 7 years, where he helped the business grow to over $400M in revenue (from $6M), to 3000 employees worldwide (from 100 employees), and improve gross margins to 50% (from -21%). Previously, Robert enjoyed a 10-year finance career as VP Corporate Analysis & Control, VP International Finance, and Assistant Corporate Controller at Boston Scientific (NYSE: BSX), a worldwide $8B medical device company operating in 40 countries.
A CPA with an MBA, Robert began his career at Deloitte & Touche, followed by 5 years at United Technologies (NYSE: UTX), a $57B multinational conglomerate and manufacturer of high technology products and provider of services to the aerospace and defense industries, where he led the worldwide financial reporting group.
Education :
Reference links :
Bill Asher , JD
Venture Partner
Business & Technology Lawyer, Board Governance, Nonprofit Advising
Bill is an adviser and mentor to early-stage organizations and entrepreneurs in both the private sector and in the nonprofit community. Prior to retiring from active legal practice, Bill spent more than 35 years working with entrepreneurs, their companies and investors in the technology and life sciences ecosystems in New England, most recently at Choate, Hall & Stewart LLP and previously at Testa, Hurwitz & Thibeault, where he also served as managing partner. A major focus of Bill's professional career has been to support and assist the development of entrepreneurial enterprises from early stage through IPO and exit.
Bill is on the board of directors of Mass Ventures, the Commonwealth’s technology venture capital fund. He has also served as a member of the executive committee of the Massachusetts Technology Collaborative Index of the Massachusetts Innovation Economy, an annual report on key technology industry clusters in Massachusetts. A member of Social Venture Partners, a Boston-based venture philanthropy organization, Bill has worked with organizations involved in foster care, food insecurity, social justice and civic education. Bill is a member of the board of directors of SVP and a leader of SVP's Center of Excellence for Governance. A member of SVP since 2016, Bill has worked directly with grantees Boston CASA, Veterans Legal Services and About Fresh.
Education :
Reference links :
Elsa Flores , PhD
Venture Partner
Researcher, Department Chair, Molecular Biology, Cancer Research
Dr. Flores is the Chair, and Senior Member Department of Molecular Oncology at Moffitt Cancer Center. Dr. Flores and her team in the Molecular Oncology Department work with the Cancer Biology and Evolution Program. This first-of-its-kind cancer center program combines findings coming from basic and clinical cancer research with biologists and mathematical oncologists to help devise new strategies and develop new agents to prevent and treat recurrent cancer.
Dr. Flores is a highly accomplished scientist who is widely published in top-tier journals and who has been awarded several distinguished research project grants (R01) from the National Cancer Institute and the Cancer Prevention Research Institute of Texas. She was named a scholar of the Rita Allen Foundation, the V Foundation and the Leukemia and Lymphoma Society of America. In 2015, Flores received the NCI’s Outstanding Investigator Award (R35). This prestigious award supports elite leaders in cancer research who are providing significant contributions toward understanding the disease and developing applications that may lead to breakthroughs. Dr. Flores is using this grant funding to identify regulatory ribonucleic acids and pathways that can be used as drug targets for the treatment of metastatic lung and skin cancer.
Prior to joining Moffitt, Dr. Flores served as the co-director of the Metastasis Research Center and member of the Basic Science Research Division at MD Anderson Cancer Center. She was also a professor of molecular and cellular oncology at The University of Texas MD Anderson Cancer Center. Dr. Flores completed her postdoctoral training at MIT.
Education :
Reference links :
Ken Tsai , MD, PhD
Venture Partner
Anatomic Pathology & Tumor Biology, Scientific Journal Editor
Dr. Tsai is a Senior Member of the Anatomic Pathology and Tumor Biology at Moffitt Cancer Center and Co-Director of the Melanoma & Skin Cancer Center of Excellence where he leads a translational research and clinical trial program for high-risk cutaneous carcinomas and lymphomas. His primary goal is to advance practice-changing care across the entire spectrum of skin cancer risk prediction, prevention, and therapy. He is a board-certified dermatologist and dermatopathologist, and the focus of his laboratory research is on (1) mechanistic preclinical testing and validation of novel therapies for aggressive cuSCC and Merkel cell carcinoma (MCC); (2) developing technologies to assess skin cancer risk and measure skin-based surrogate pharmacodynamic endpoints in cancer therapy; and (3) identifying cancer signaling vulnerabilities and novel combinations with immunotherapies.
Prior to Moffitt, Dr. Tsai was an Associate Professor at MD Anderson Cancer Center where he led a NIH and CPRIT funded research program focused on cutaneous squamous cell carcinoma, signaling pathways in melanoma and responses to therapy, and biomarker development for skin cancer risk and prediction of therapeutic responses. During this time he was also an attending dermatologist and dermatopathologist at UT Health Science Center Houston where he practiced dermatopathology and dermatology, with clinical teaching of dermatology and pathology residents and fellows.
As a member of the Editorial Boards for the Journal of the American Academy of Dermatology and Cancer Research, Dr. Tsai provides editorial input for articles considered for publication and reviews extensively for other high-profile journals. He is also a standing member of the NIH Center of Scientific Review Cancer Etiology study section and the NCI PREVENT review panel.
\"Chance favors only the prepared mind.\" - Louis Pasteur
Education :
Reference links :
Leo Tsai , MD, PhD, MSc
Venture Partner
Academic Faculty, Oncologic Imaging & Radiology, Medical Devices
Dr. Tsai is the Director of MRI at Beth Deaconess Medical Center and Assistant Professor of Radiology at Harvard Medical School. He is an abdominal radiologist with expertise in cancer and lymphatic imaging. He received an M.Sc. in Medicinal Chemistry from Cambridge University, PhD in Biophysics from Harvard University, and an MD from Harvard Medical School under the Harvard-HST Division of Health Sciences and Technology (HST) program. His research focuses on the development of new MRI biomarkers in detecting cancer progression and treatment response. Dr. Tsai is also co-Founder and Chief Medical Consultant of Agile Devices Inc., a microcatheter company based in Boston, MA.
Education :
Reference links :
Howard Levine , PhD
Venture Partner
Biopharmaceutical Manufacturing, Commercialization, Professional Services
Howard L. Levine is currently the National Leader of the BioProcess Technology Group, a part of the life sciences practice of BDO USA, LLP, one of the nation’s leading professional services companies. Dr. Levine is a pioneer and thought leader in the biopharmaceutical industry with extensive strategic and operational experience in biopharmaceutical product development and commercialization.
In his 40 years in the biopharmaceutical industry, Dr. Levine has assisted numerous companies in developing biological products, provided strategic input in the development of new manufacturing technologies, and participated in the successful commercialization of several of these products.
In 1994, Dr. Levine founded BioProcess Technology Consultants (BPTC), a biologics CMC consulting firm, that provided a full range of technical, regulatory, and strategic assistance related to the development and commercialization of biopharmaceutical products. BPTC assisted clients in developing manufacturing processes and strategies that enhanced the overall value of their products, while de-risking product development. BPTC also helped investors, service providers, and companies make informed decisions by providing technical due diligence services and business evaluations of new products as well as technologies for product discovery, development, or commercialization. Dr. Levine served as President, and CEO of BPTC until it was acquired by BDO in 2019.
Prior to founding BPTC, Dr. Levine was Vice President of Manufacturing Operations at Repligen Corporation, a bioprocessing-focused life sciences company. Previously Dr. Levine held positions of increasing responsibility in process development and manufacturing at Genentech, Amgen, and Xoma.
Dr. Levine is a frequently invited lecturer on manufacturing strategy, downstream processing, and commercialization of biotechnology products and an author of numerous, peer-reviewed publications. He holds a Ph.D. in chemistry from the University of Chicago and completed a post-doctoral fellowship at Harvard University.
Education :
Reference links :
Lisa Frusztajer , MBA, MSc
Venture Partner
Marketing & Management Consulting, Technical Advising, Venture Capital
Lisa is a highly active angel investor in Boston. She is a Venture Partner with the Portfolia Enterprise Fund, supporting its portfolio of companies in the software, internet, digital media, SaaS, robotics and other cutting-edge information technology spaces. She is a Limited Partner of Converge Venture Partners. Lisa is currently Investor in Residence at The Capital Network, a Boston-based non-profit that educates and mentors entrepreneurs on how to get their startups off the ground, and that connects investors with founders. Lisa is an alumna of the Pipeline Fellowship, a training fellowship for investors. Lisa is an alumna of the Pipeline Fellowship, a training fellowship for investors.
Lisa has navigated all ends of the technology world over the last twenty years, first working at Sun Microsystems, then growing a small software startup called KYOS, and joining Avid Technology, the leading provider of audio and video technology for media organizations and independent professionals.
Lisa is currently focusing on angel investing and consulting projects. Her background is an eclectic blend of marketing, engineering and project management, as well as of technology, manufacturing, higher education and finance. She has served on a number of non-profit boards, mainly in education.
Education :
Reference links :
Luke S. Oh , MD
Venture Partner
Orthopaedic Surgeon, Sports Medicine Specialist, Clinical Scientist, Healthcare & MedTech Advisor
Dr. Luke Oh is a practicing surgeon, medical educator, research scientist, entrepreneur and innovator. Dr. Oh is a Board Certified Orthopaedic Surgeon with a Subspecialty Certificate in Sports Medicine. He is Assistant Professor of Orthopaedic Surgery at Harvard Medical School, and has a full-time academic surgical practice at Massachusetts General Hospital. After residency at the Hospital for Special Surgery, Dr. Oh completed multiple subspecialty fellowships including Sports Medicine & Arthroscopy at MGH, Shoulder & Elbow Surgery at the Mayo Clinic, and an apprenticeship with Dr. James Andrews to master the techniques for Tommy John surgery for professional baseball players.
Dr. Oh is the Emeritus Fellowship Director of the Harvard-MGH Orthopaedic Sports Medicine Fellowship and a faculty member of the Harvard Shoulder & Elbow Fellowship, MGH Primary Care Sports Medicine Fellowship, and the Harvard Combined Orthopaedic Residency Program. He is also the Medical Director for the Futures Collegiate Baseball League, team physician for the Boston Red Sox and New England Revolution, and consultant for the New England Patriots, Boston Bruins and Harvard University.
Dr. Oh's clinical reputation and cutting-edge research have garnered national and international recognition. His clinical and research interests include treatment of shoulder & elbow injuries in the throwing athlete, rotator cuff tears, ACL rupture, meniscus tears, and osteochondritis dissecans. Dr. Oh's current research includes artificial intelligence for diagnosis and treatment in orthopaedics; biomechanical investigation of various surgical techniques; and, tissue engineering to improve healing of the rotator cuff, biceps, ACL, and meniscus.
In addition to his career in orthopaedics, Dr. Oh is a strategy advisor for both mature and early stage companies in healthcare innovations, medical devices, tissue engineering, artificial intelligence, and emerging technologies.
Education :
Reference links :
Austin Che , PhD
Venture Partner
Co-founder, Biotechnology, Computer Science
Austin Che is a cofounder of Ginkgo Bioworks along with three classmates and his PhD advisor. Headquartered in Boston, Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo is also actively supporting a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery. In 2021, Ginkgo became a public company at a $15 billion pre-money valuation via acquisition by Soaring Eagle Acquisition Group, a publicly traded special purpose acquisition company (SPAC).
Education :
Reference links :
Randy Bak , MD, JD
Venture Partner
Dr. Bak is a pediatrician and attorney who has worked across settings in healthcare, with experience in health information technology and product development. After training in Seattle, he practiced in the acute care setting at a regional children’s hospital while studying for his law degree, with an emphasis on health systems and their regulation. As part of the leadership team of a primary care practice, he led the development of information technology capabilities for what became a system of more than 80 doctors at seven sites.
Dr. Bak returned to the hospital setting for his clinical practice in Boston, working for a community hospital affiliated with a large academic health system. With this move, he also took on industry work beginning with a technology-forward, primary-care-founded Medicare Advantage health plan. He joined an internal start-up that commercialized their systems and processes to offer software and services to organizations attempting collaborative care between payers and providers. He continued in similar roles, supporting a platform for payer-provider collaboration on administrative processes, patient-matching for clinical trials in cancer, and commercialization efforts at a cancer- and diabetes-focused digital therapeutics company.
Along the way, he has used his expertise of clinical and administrative processes and funds flow in healthcare to support product management and implementation efforts, translating the voice of healthcare customers for emerging and growing companies. He has also assisted sales and marketing teams, translating information technology value and opportunity back to the healthcare community.
Raised in Philadelphia, he graduated from Dartmouth College, summa cum laude, with a BA in Philosophy. He returned home to Temple University School of Medicine before a pediatrics residency at Seattle Children's Hospital. He received his JD from the University of Washington. While in Boston, he has served on the Massachusetts Medical Society Committee on Information Technology. He is also a member of the Clinical Advisory Group of the Digital Therapeutics Alliance.
Education :
Reference links :
Steven Brunelli , MD, MSCE
Venture Partner
Data Analytics | Regulatory
Steven Brunelli MD MSCE is vice president for clinical research at a national healthcare provider. In that role he is responsible for generating evidence that sets the organization’s clinical strategy as well as developing new products.
He has extensive experience in drug and device development including registrational studies, market sizing and establishment of value propositions. Prior to his current role, Dr Brunelli was a faculty member at Harvard Medical School and Brigham and Women’s Hospital, where he led active research programs in both nephrology and pharmacoepidemiology and was clinical director of the organization’s dialysis operations.
He holds a BS in Chemistry from MIT and an MD and MSCE (clinical epidemiology) from the University of Pennsylvania.
Education :
Reference links :
Celine Gounder , MD, ScM
Innovation Council
Medical Analyst, Media Host, Infectious Disease Specialist, Epidemiologist
Dr. Gounder is the CEO/President/Founder of Just Human Productions, a non-profit multimedia organization. She’s also the host and producer of American Diagnosis, a podcast on health and social justice, and Epidemic, a podcast about the SARS-CoV-2 / COVID-19 / coronavirus pandemic.
From November 9, 2020 to January 20, 2021, Dr. Gounder served on the Biden-Harris Transition COVID-19 Advisory Board.
She is a CNN Medical Analyst, and prior to that, was a frequent expert guest on MSNBC, CNBC, HLN, Al Jazeera America, CBS, BBC, MTV, Dr. Oz, and Oprah Prime. She's written for The New York Times, The New Yorker, The Atlantic, The Guardian US, The Washington Post, Reuters, Quartz, Sports Illustrated, and Bloomberg View. She’s best known for her coverage of the Ebola, Zika, COVID-19, opioid overdose, and gun violence epidemics.
Dr. Gounder is a Clinical Assistant Professor of Medicine and Infectious Diseases at New York University’s Grossman School of Medicine. She cares for patients on the wards at Bellevue Hospital Center.
In early 2015, Dr. Gounder spent two months volunteering as an Ebola aid worker in Guinea. In her free time, she interviewed locals to understand how the crisis was affecting them. She is currently making Dying to Talk, a feature-length documentary about the Ebola epidemic in Guinea.
Between 1998 and 2012, she studied TB and HIV in South Africa, Lesotho, Malawi, Ethiopia, and Brazil. While on faculty at Johns Hopkins, Dr. Gounder was the Director for Delivery for the Gates Foundation-funded Consortium to Respond Effectively to the AIDS/TB Epidemic. She later served as Assistant Commissioner and Director of the Bureau of Tuberculosis Control at the New York City Department of Health and Mental Hygiene.
She received her BA in Molecular Biology from Princeton University, her Master of Science in Epidemiology from the Johns Hopkins Bloomberg School of Public Health, and her MD from the University of Washington. Dr. Gounder was an intern and resident in Internal Medicine at Harvard’s Massachusetts General Hospital, and a post-doctoral fellow in Infectious Diseases at Johns Hopkins University. She was elected a fellow of the Infectious Diseases Society of America in 2016 and featured in the IDSA’s 2017 Annual Report. In 2017, People Magazine named her one of 25 Women Changing the World. In 2021, InStyle Magazine named her one of 50 Women Making the World a Better Place.
Education :
Reference links :
Fatima Cody Stanford , MD, MPH, MPA, MBA, FAAP, FACP, FAHA, FAMWA, FTOS
Innovation Council
Obesity Medicine & Nutrition, Medicine Advocacy, | Health Communications
Dr. Stanford practices and teaches at Massachusetts General Hospital (MGH)/ Harvard Medical School (HMS) as one of the first fellowship-trained obesity medicine physicians in the world. Dr. Stanford received her BS and MPH from Emory University as a MLK Scholar, her MD from the Medical College of Georgia School of Medicine as a Stoney Scholar, her MPA from the Harvard Kennedy School of Government as a Zuckerman Fellow in the Harvard Center for Public Leadership, and her MBA at the Quantic School of Business and Technology as a merit-based scholar. She completed her Obesity Medicine & Nutrition Fellowship at MGH/HMS after completing her internal medicine and pediatrics residency at the University of South Carolina. She has served as a health communications fellow at the Centers for Disease Control and Prevention and as a behavioral sciences intern at the American Cancer Society. Upon completion of her MPH, she received the Gold Congressional Award, the highest honor that Congress bestows upon America’s youth.
Dr. Stanford has completed a medicine and media internship at the Discovery Channel. An American Medical Association (AMA) Foundation Leadership Award recipient in 2005, an AMA Paul Ambrose Award for national leadership among resident physicians in 2009, she was selected for the AMA Inspirational Physician Award in 2015. The American College of Physicians (ACP) selected her as the 2013 recipient of the Joseph E. Johnson Leadership Award and the Massachusetts ACP selected her for the Young Leadership Award in 2015. She is the 2017 recipient of the HMS Amos Diversity Award and Massachusetts Medical Society (MMS) Award for Women’s Health. In 2019, she was selected as the Suffolk District Community Clinician of the Year and for the Reducing Health Disparities Award for MMS. She was selected for The Obesity Society Clinician of the Year in 2020. In 2021, she will be awarded the AMA Dr. Edmond and Rima Cabbabe Dedication to the Profession Award which recognizes a physician who demonstrates active and productive improvement to the profession of medicine through community service, advocacy, leadership, teaching, or philanthropy.
Education :
Reference links :
receive regular updates & exclusive previews
Leave your message & we'll get back to you shortly
We use cookies to analyse our traffic. You accept the use of cookies by closing or dismissing this notice, by clicking a link or button, or by continuing to browse otherwise. Please check our Privacy Policy for the full story on how we protect and manage your submitted data.
Home 
Mission 
Third Culture Kids 
About us 
Our Portfolio 
Our Team 
Share your startup/Origin story 
Newsroom 
Newsletters 
Resources 
Third Culture Repository 
Media/General contact 
